Rogaratinib

洛伽替尼

Report date: 2026/02/16 20:01:25
NME

Base Information

Drug NameRogaratinib
Drug Alias NameRogaratinibumBAY-1163877
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonists +[4] 
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 2Fibroblast growth factor receptor 3 +[4] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteBayer AG
Inactive CompaniesDana-Farber Cancer InstituteSwiss Group for Clinical Cancer Research (SAKK)Bayer Healthcare Company Ltd
Active IndicationsMetastatic breast cancerBreast NeoplasmsSarcoma +[4] 
Inactive IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 

Other Information

ATC CodeN/A
Related LinksN/A